Abstract. The positron-emitting radiohalogens 18 F, 75 Br, 76 Br, and 124 I are reviewed regarding their relevance for positron emission tomography (PET) in oncology. Relevant production routes of these cyclotron-generated isotopes are given, followed by publications that deal with applications of these radiohalogens. This article tries to cover the whole literature for the non-conventional isotopes 75 
Introduction
PET in oncology. Positron emission tomography (PET) is a modern and powerful technology to study non-invasively biological processes at the molecular level (1, 2) . This highly sophisticated imaging method relies on coincidence registration of annihilation photons having a characteristic energy of 511 keV. Advantages of PET over single photon emission tomography (SPECT) are the high sensitivity and spatial resolution, and ability to give quantitative answers. PET can thus be used to study pharmacokinetics and mechanism of action of drugs.
Besides many other applications, radiolabelled PET tracers can also be used to investigate lesions such as carcinomas. Here, PET is employed for diagnosis and staging of diseases as well as judging the efficacy of anti-cancer drugs (3) . Generally, the result will reflect changes in biochemistry rather than morphology. Thus, PET has always to be considered being complimentary to 'conventional' means of imaging such as computed tomography (CT) or magnetic resonance imaging (MRI).
There is a wide range of positron-emitting halogens available -with fluorine-18 as the most prominent among them. The aim of this article is to review the use of those radiohalogens in respect to PET oncology. There are already several excellent reviews available that cover fluorine-18 applications in oncology (4) (5) (6) (7) . Thus, only the literature from 2000 to 2002 will be considered here.
In recent years a number of alternative PET halogens with relevance to oncology have also emerged. These radionuclides may not be as ideal as fluorine-18 in terms of radiophysical properties but owing to the prolonged half-life they can be shipped with less time constraints to nuclear medicine departments away from cyclotrons. This fact is also underlined by the new trend towards dual-head SPECT/PET cameras (8) . Accordingly, the use of those alternative radiohalogens implies also different approaches of radiochemistry.
Positron-emitting halogens.
A comprehensive list of medically relevant non-conventional positron emitters has been reviewed by Pagani et al (8) . Here, we will focus on the positron-emitting halogens 18 F, 75 Br, 76 Br, and 124 I which have been reported to be useful for applications in oncology. Table I compares some selected physical properties of these radioisotopes.
Generally, the decay of 75 Br, 76 Br, and 124 I results in positrons of higher energy compared with 18 F. This means a loss in spatial resolution since the positrons take a longer distance in tissue until annihilation. These alternative radiohalogens also emit Á-rays of high energy resulting from electron capture ( 75 Br, 76 Br, 124 I) and internal transitions ( 124 I). 75 Br has a half-life of the similar order of magnitude as 18 F. However, it produces the long-lived daughter nuclide 75 Se (t 1/2 = 120 days). The latter isotopes have a relatively long half-life which is an advantage for the radiosyntheses and the investigation of long-term biological processes. Although the disintegration of 76 Br and 124 I results in the stable isotopes 76 Se and 124 Te, respectively, the increased effective dose might become a limiting factor in clinical trials.
Applications of fluorine-18 labelled radiopharmaceuticals in oncology. [ 18 F]FDG. The success of PET as a diagnostic tool in nuclear medicine is mainly due to the use of [ 18 ]2-fluoro-2-deoxyglucose ([ 18 F]FDG) -not only in oncology, but also in cardiology and neurology (17) . [ 18 F]FDG has become a valuable diagnostic tool with numerous applications: Fig. 1 illustrates the popularity of [ 18 F]FDG as a substantial increase in the number of publications on the subject. The term 'PET oncology' is usually seen as a synonym of the application of [ 18 (3, 7, (12) (13) (14) (15) . Lists of types of tumours that have been diagnosed by [ 18 F]FDG-PET can be found in refs. 6 and 11. The method has also been comprehensively reviewed for more than 20 tumours in terms of sensitivity, specifity and percent in management change by Gambhir et al (151) . Fig. 2 ) is a thymidine analogue. After the incorporation of FLT into the DNA, the lack of the 3'-hydroxy group causes the termination of the DNA polymerization. It appears that [ 18 F]FLT may be associated with proliferation and has the potential to become a clinically useful radiopharmaceutical (17, 169) .
The radiochemistry and biology of [ 18 F]FLT has been recently summarised by Mier et al (18) . Previously, [ 18 F]FLT Table I . Some decay properties of the halogens reviewed in this article (data from ref. 8 ).
- could be obtained in only moderate radiochemical yields (19) . Martin et al have now introduced a new precursor with improved deprotection chemistry (Fig. 2) (30) (31) (32) . A melanoma-bearing mouse was investigated by PET and showed a high tumour/blood ratio of 27.5 after 120 min post injection. This suggests that [
18 F]Galacto-RGD might potentially be a promising PET tracer for imaging angiogenesis.
As a further angiogenesis marker, squalamine, a natural aminosterol from tissues of dogfish sharks, has been radiofluorinated with 1-[
18 F]fluroro-3-tosylpropane (33) . The biological evaluation of this tracer is still in progress.
Fluorine-18 labelled amino acids. It is assumed that the increased metabolism of tumours also involves a faster protein synthesis. Thus, in the search for tumour specific tracers as better alternatives to [ 18 F]FDG there has been much effort in evaluating radiolabelled amino acids. Fluorine-18 is seen as a better radioisotope compared to carbon-11, because the longer half-life matches the protein metabolism more appropriately. A review by Laverman et al gives a summary on 18 Ffluorinated amino acids as relevant for oncology (34) . In order to achieve metabolically stable tracers, several non-natural radiolabelled amino acids have been prepared. These compounds should act as pure markers for the transport of amino acids. Martarello There is also a short communication on uptake profiles and transport mechanism of these two groups of amino acid radiotracers (167) . Thus, the non-natural 18 F-fluorinated amino acids should become an intriguing field for PET oncology.
Fluorine-18 labelled peptides. Fluorine-18 labelled peptides are another interesting field of PET oncology research. Sutcliffe- 
Goulden et al used p-[
18 F]fluorobenzoic acid as prosthetic group to label RGD peptides (39) . The radiosynthesis of p- [ 18 F]fluorobenzoic acid was carried out with 80-90% decay corrected radiochemical yield using an FDG synthesizer. The following incubation with immobilized peptide took only 2 min and gave the labelled peptides in yields >90% and high purity. Unfortunately, the peptides were broken down within 5 min in vivo.
Bergmann et al radiofluorinated analogues of the neuropeptide neurotensin as complementary PET tracer to the somatostatin receptor (40) (44) . This receptor was found in many in vitro and in vivo tumour models. Two highaffinity thiazolidine compounds have been radiofluorinated. Unfortunately, no selective tumour uptake or retention could be observed in mice bearing human xenografts of breast cancer.
Bonasera et al published a number of 18 F-labelled 4-(anilino) quinazolines for potential mapping of the epidermal growth factor receptor tyrosine kinase (EGFr-tk) (45) . However, despite good data from cell culture, kinetic factors and a rapid blood clearance prevented useful PET imaging in tumour-bearing mice. The 18 F-chemistry of labelled steroid molecules for imaging breast tumours has been reviewed in an article by Katzenellenbogen (46) . There are many synthetic methods available. However, it is still difficult to prepare ligands with high specific radioactivity from compounds that have electron-rich rings and are not accessible to nucleophilic aromatic substitution reactions.
Bromine-75
Production of bromine-75. The production methods of 75 Br have been comprehensively reviewed in the past (9,47-52). Applications of bromine-75 labelled radiopharmaceuticals in oncology. The introduction of bromine into biologically active molecules for PET offers two advantages over other halogenation reactions. First, bromine chemistry is easier to handle than fluorine chemistry and secondly, compared with iodination, the bromine radiotracers are expected to be much more stable in vivo due to the higher binding energy of bromine-carbon.
Bromine-75 has been used for recoil labelling, but the more common method is direct electrophilic substitution including enzymatic protocols (51,53). There are not many examples for the use of 75 Br in tracers with relevance for PET oncology so far. This might be due to the cyclotron production requiring a relatively high beam energy which is available only in a few centres. Furthermore, there are difficulties in the targetry and target chemistry of the radioisotope. Whereas the short halflife of 75 Br is clearly favourable for applications in nuclear medicine, the biological effect of the long-lived daughter isotope 75 Se (t 1/2 = 120 days, E Á = 864 keV) has not been fully investigated yet.
Kloster 75 Br]BMT was obtained with 85% radiochemical yield. PET scans from mice revealed a rapid pancreas uptake, which was 9.7±1.4-fold higher than the liver uptake.
Terpstra et al mentioned in an abstract the labelling of estrogens to measure the density of estrogen receptors in breast cancer (55) -however without biological evaluation. ------------------------------------------------ 
9). -------------------------------------------------Nuclear reaction Energy range Theoretical thick target (MeV) yield (MBq/µAh) -------------------------------------------------

Bromine-76
Production of bromine-76. Table IV gives a short summary of the production methods for 76 Br. The preferred method for the generation of 76 Br by a low-energy cyclotron is the 76 Se(p,n) 76 Br reaction with a practial yield of 70 MBq/µAh (56 Fig. 5 ) was prepared from a 5-trimethylstannyl precursor for the first time by Koziorowski and Weinreich (59). Bergström et al investigated the biodistibution of this proliferation tracer in Sprague-Dawley rats and pigs (60) . The rats showed high tracer uptake in all organs, that was not related to DNA incorporation. In the pigs the highest incorporation was found in the red bone marrow with 70-80% DNA incorporation. However, the correction for [ 76 Br]bromide was a problem for the PET analysis. A subsequent study from the same group aimed at solving the issue of high background by the use of diuretics in rats -with partial success (61 75 As( 3 He,2n) 76 Br 18➝10 11 76 Se(p,n) 76 Br 16➝10 296 77 Se(p,2n) 76 Br 25➝16 259  ------------------------------------------------ Table V . Summary of studies on antibodies labelled with 76 Br. 
9). -------------------------------------------------Nuclear reaction Energy range Theoretical thick target (MeV) yield (MBq/µAh) -------------------------------------------------
b Anti-blood group Lewis y ; c Anti-carcinoembryonic antigen; d Accumulation index = 2.9±0.8% (i.e., tissue weighted maximum tumour uptake). 76 Br]p-SBB in a preliminary study to label doxorubicin and daunorubicin as potential PET marker for multidrug resistance (143) . The tracers were tested on rat fibrosarcoma cells but no data was given.
-------------------------------------------------
Iodine-124
Production of iodine-124. A summary of the production methods for 124 I including isolated yields is given in Table VI . The very first attempts to produce 124 I by a cyclotron used natural antimony as target material for · particles (71, 72) . However, the achievable target yields were rather poor. The antimony route was re-investigated recently (73) . Better results have been obtained later with proton and deuteron irradiation of targets made of isotopically enriched tellurium. Early radiochemists used demanding wet chemistry methods to extract 124 I from antimony targets. Wet chemistry was also employed to extract the radioiodine from 124 Te target material after a (d,2n) reaction. This area was pioneered by Lambrecht and co-workers (74) (75) (76) (77) (78) .
The more convenient technique of dry distillation was introduced by van den Bosch et al (79) . The method has seen many attempts for improvement and refinement since then (80- 124 I reaction leads to very high yields of 124 I, but produces also considerable amounts of 125 I (89). The 125 I impurity is also significant in the 124 Te(d, 2n) 124 I process (90) . It arises here from the 124 Te(d,n) 125 I reaction, which cannot be suppressed. The 124 Te(p,n) 124 I reaction gives the best radionuclidic purity of 124 I but has a lower thick target yield (81, 91) . Here the extent of 125 I byproduct only depends on the level of enrichment of 124 Te material. The 123 Te(d,n) 124 I reaction was investigated by Scholten et al but was found to be not useful in terms of reasonable target yield of 124 I and impurity level of 123 I (98). 
Applications of iodine-124 labelled radiopharmaceuticals in oncology. General. When iodine-124 became available to clinical medicine from dedicated cyclotrons 40 years ago, it was perceived as alternative therapeutic radionuclide to reactor produced iodine-131. It was also recognized, that the highenergy positrons from incorporated 124 I should have a similar effect in tissue as ß -particles from 131 I. In vivo experiments showed a more uniform radiation dose of 124 I compared to 131 I. With 124 I, the accuracy of the measurements could be improved by coincidence detection (71) .
However, the rather demanding nature of early radiochemistry, the complex decay scheme, the low abundance of positrons, and an unfavourable dosimetry (99), can all be seen as impediments to the widespread use of 124 I.
In 1996 Pentlow et al published a study on tumour-like phantom sources of 124 I using several PET scanners (100). The authors concluded that quantitative imaging with 124 I can give results of almost the same quality as 18 F. The loss in spatial resolution was found to be similar as in images obtained by conventional PET nuclides. A recent study by Herzog et al came to the same conclusion with the statement that quantitation of 124 I imaging might be further improved by developing of specific corrections (101) . New prospects are opening up with the introduction of 124 I-PET-CT imaging (102, 150) . Other applications of 124 I are listed below.
As mentioned earlier, 124 I can be used as therapeutic radioisotope. In fact, the calculated effective dose is in the same order of magnitude as 131 I. For example, the effective dose of 124 I is 1.5 mSv/MBq and for 131 I 2.4 mSv/ MBq -assuming a 35% thyroid uptake in both cases (103) .
Possibly the first reported 124 I scan was performed on a rat thyroid (71) . The first clinical case of thyroid carcinoma treatment with 124 I was published in 1960 (104) . The rather low amounts of 124 I producible at that time were a limiting factor. Lambrecht et al reported the first PET scan of thyroid carcinoma (105) . A combined dose of 124 I and 131 I has been used to treat hyperthyroidism with accompanying PET (106). Ott et al used 124 I scans in Grave's disease before and after thyroectomy (107) .
The real virtue of [ 124 I]iodide can probably be seen in the use of its positron component to work out the functional volume of thyroids. This information is needed as accurately as possible in order to calculate the individual dosimetry of patients undergoing 131 I therapy for thyrotoxicosis (102, (108) (109) (110) (111) . The functioning volume of the thyroid of 22 patients could be determined by 124 I with an accuracy of ±4-14% (112). Frey et al examined thyroids of 38 patients with 124 I-PET. The investigators observed considerable regional uptake differences in multinodular goitres (181) . Flower et al carried out a doseresponse study on 65 patients using 124 I-PET scans in order to calculate the 131 I dose that would be needed to achieve euthyroidism (113) .
The benefits of [ 18 F]FDG have been recently combined with 124 I for evaluation of glucose and iodide metabolism in suspected recurrent thyroid carcinoma (174) .
[ 124 ] IUdR. The use of carbon-11 labelled thymidine as a marker of tumour cell proliferation is limited by the short half-life of 11 C (t 1/2 = 20 min) because it does not cover the time that is needed for sufficient clearance of unbound tracer and metabolites. Therefore, metabolite correction with complex models needs to be carried out (114) . Consequently, the 124 I analog of thymidine 5- Fig. 7 ) has been synthesised by Blasberg et al and used in a study of 20 patients with various brain tumours including meningiomas and gliomas (115) . The investigators measured the incorporation clearance constant (K i ), standard uptake value (SUV) and tumour/brain radioactivity concentration, that were all related to tumour type and grade, tumour labelling index, and survival after the PET scan. However, the rapid metabolic degradation of the tracer in blood was seen as a disadvantage. 124 I]FIAU has also been used to detect differential viral infectivity of three HSV variants (178) and for monitoring the transcriptional activiation of p53-dependent genes by a dual reporter gene (HSV1-tk/GFP) (177 124 I. 
b Maximum tumour uptake; c Human tumour, expressing placental alkaline phosphatase, PLAP; d c-erbB-2 proto-oncogene product;
e Vascular endothelial growth factor.
-
including sporadic and extra-adrenal lesions as well as medullary hyperplasia have been diagnosed with this compound (123, 124) . Using the ammonium sulfate (125) or copper(II) nitrate (76) assisted isotopic exchange reactions, the 124 I analogue of mIBG (Fig. 7) has been prepared. The radiochemical yields were 89-98% and 70-90%, respectively. Ott et al used [
124 I]mIBG in a clinical study to predict the corresponding 131 I radiation doses for the whole body, normal liver and neural crest tumours (126) . Uptake was found in various tumour sites in lung, liver, and abdomen.
Antibodies labelled with 124 I. The use of antibodies for tumour diagnosis and therapy clearly benefits from the long half-life of 124 I. For instance, an IgG antibody has an effective biological half-life of 48 h, which is well compatible with iodine-124's t 1/2 of 4.2 days (127) . Again, the use of 124 I labelled antibodies might provide dosimetry information for radioimmunotherapy (RIT) (128) . The potential use of 124 I labelled antibodies in radiotherapy has also been claimed by a patent (129) . The majority of the labelling has been carried out by established electrophilic substitution reactions on tyrosine side chains (130) . However, there are also reports describing the use of lysine conjugation via the Bolton-Hunter reagent (97, 131, 132 ).
An overview of several applications for 124 I labelelled antibodies in oncology is given in Table VII . Most of these studies do report on studies using animal xenografts of human tumours. The slow pharmacokinetics of antibodies can be seen as a considerable disadvantage in RIT. However, the renewed interest in the antibody approach arises from the availability of genetically engineered 'minibodies' (133) , and endothelial targets that are exposed during angiogenesis (97, 132, 134) . 124 I and MDR. Iodine-124 could also be a useful radioisotope to investigate the phenomenon of multidrug resistance (MDR) that occurs during chemotherapy. In a preliminary report Sosabowski et al prepared the N-p- [ 124 I]iodobenzoyl derivatives of doxorubicin and daunorubicin, respectively (Fig. 7) . The researchers tested the tracers on inherently resistant rat fibrosarcoma cells, that express both MDR proteins (P-gp and MRP). The data showed that the new compounds are substrates for MDR proteins and might be useful in further in vivo applications on this subject. At present, the 99m Tc tracer Sestamibi is dominating this field (143) . [ 124 I]Iodocolchicine (Fig. 7) is another promising candidate for probing MDR with PET. However, there are no data available yet (142) .
[
124 I]annexin-V. During the complex phenomenon of genetically programmed cell death, or apoptosis, cell membranes are reverting before rupture, and are exposing phosphatidylserine residues. The 36 kDa proteine annexin-V binds with high affinity to these surfaces (K = 10 -9 M). Thus, this biomolecule has the potential to become a radiotracer in PET diagnosis of apoptosis during oncolytic therapy (144, 145) . Iodine-124 was the first PET nuclide to be used to synthesise such a radiopharmaceutical as a marker for apoptosis (146 
Conclusions
Positron-emitting radiohalogens are playing an increasingly important role in PET oncology. The last two decades have also seen considerable improvements in the generation of useful PET radiohalogens by medical cyclotrons as well as in the corresponding target chemistry. Whereas the clinical potential of tracers containing the non-conventional 76 Br or 124 I may be seen as rather low, these probes are very useful in preclinical experiments such as in those using small animal scanners (e.g. for testing new anticancer drugs). Studies for PET based imaging of biological processes on a molecular level might also benefit from the longer half-life of 76 Br and 124 I. The labelling of peptides and proteins with positronemitting halogens still needs the development of techniques of generic value.
